Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Im

Showing results (151-160 of 165) with videos related to

Pageof 17
Sort By:
Leukemia & Lymphoma|November 3, 2005
IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomasB-B Park, W S Kim, J Lee, et al.
Investigational New Drugs|May 17, 2013
A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancerK H Park, J H Sohn, S Lee, et al.
Medical Oncology (Northwood, London, England)|October 1, 2004
Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancerS-H Lee, J Lee, J Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2015
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trialG Bianchini, L Pusztai, T Pienkowski, et al.
Neuroscience|May 29, 2003
Immunocytochemical evidence that amyloid beta (1-42) impairs endogenous antioxidant systems in vivoH-C Kim, K Yamada, A Nitta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2018
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trialJ Ettl, R G W Quek, K-H Lee, et al.
Ophthalmology Science|April 7, 2023
A Multicenter Analysis of Nucleic Acid Quantification Using Aqueous Humor Liquid Biopsy in Retinoblastoma: Implications for Clinical TestingDeborah H Im, Sarah Pike, Mark W Reid, et al.
Oncotarget|October 27, 2016
Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effectEsther A Kleibeuker, Emmanouil Fokas, Philip D Allen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 24, 2020
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trialJ K Litton, S A Hurvitz, L A Mina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2022
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE studyH S Rugo, J O'Shaughnessy, F Boyle, et al.
Pageof 17

Showing results (151-160 of 165) with videos related to

Sort By:
Pageof 17
Leukemia & Lymphoma|November 3, 2005
IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomasB-B Park, W S Kim, J Lee, et al.
Investigational New Drugs|May 17, 2013
A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancerK H Park, J H Sohn, S Lee, et al.
Medical Oncology (Northwood, London, England)|October 1, 2004
Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancerS-H Lee, J Lee, J Park, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2015
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trialG Bianchini, L Pusztai, T Pienkowski, et al.
Neuroscience|May 29, 2003
Immunocytochemical evidence that amyloid beta (1-42) impairs endogenous antioxidant systems in vivoH-C Kim, K Yamada, A Nitta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2018
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trialJ Ettl, R G W Quek, K-H Lee, et al.
Ophthalmology Science|April 7, 2023
A Multicenter Analysis of Nucleic Acid Quantification Using Aqueous Humor Liquid Biopsy in Retinoblastoma: Implications for Clinical TestingDeborah H Im, Sarah Pike, Mark W Reid, et al.
Oncotarget|October 27, 2016
Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effectEsther A Kleibeuker, Emmanouil Fokas, Philip D Allen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 24, 2020
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trialJ K Litton, S A Hurvitz, L A Mina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2022
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE studyH S Rugo, J O'Shaughnessy, F Boyle, et al.
Pageof 17